Bio-Reference Laboratories Hits Estimates in Solid Quarter
Bio-Reference Laboratories (NAS: BRLI) reported earnings on June 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended April 30 (Q2), Bio-Reference Laboratories met expectations on revenues and met expectations on earnings per share.
Compared to the prior-year quarter, revenue grew. GAAP earnings per share expanded significantly.
Gross margins contracted, operating margins increased, net margins increased.
Bio-Reference Laboratories booked revenue of $176.5 million. The five analysts polled by S&P Capital IQ predicted revenue of $176.1 million on the same basis. GAAP reported sales were 8.0% higher than the prior-year quarter's $163.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.41. The five earnings estimates compiled by S&P Capital IQ predicted $0.41 per share. GAAP EPS of $0.41 for Q2 were 24% higher than the prior-year quarter's $0.33 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 45.7%, 490 basis points worse than the prior-year quarter. Operating margin was 11.7%, 140 basis points better than the prior-year quarter. Net margin was 6.4%, 70 basis points better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $183.5 million. On the bottom line, the average EPS estimate is $0.52.
Next year's average estimate for revenue is $712.4 million. The average EPS estimate is $1.79.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 310 members out of 330 rating the stock outperform, and 20 members rating it underperform. Among 107 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 101 give Bio-Reference Laboratories a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Reference Laboratories is outperform, with an average price target of $32.50.
Is Bio-Reference Laboratories the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Bio-Reference Laboratories to My Watchlist.
The article Bio-Reference Laboratories Hits Estimates in Solid Quarter originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. TMFDisclosureHere
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.